Pro-inflammatory biomakers in depression: Treatment with venlafaxine
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
High levels of pro-inflammatory biomarkers have been reported in depression. In the present study, five pro-inflammatory biomarkers were measured in the blood of patients with major depressive disorder (MDD). Biomarker levels were compared to age- and sex-matched healthy subjects. Patients with MDD had significantly higher baseline levels of tumour necrosis factor-alpha (TNFalpha, P=0.04), interleukin-1beta (IL1beta, P=0.03), and monocyte chemotactic protein-1 (MCP-1; P=0.02) compared to controls. There were no differences between groups in levels of cell determinant-40 ligand (CD40L) and C-reactive protein (CRP). A subset of the MDD patients consented to undergo treatment with venlafaxine (an SNRI: at lower doses a selective serotonin reuptake inhibitor; at higher doses also a norepinephrine reuptake inhibitor) for 8 weeks. By week 8, all treatment completers had responded therapeutically. However, levels of TNFalpha, IL1beta, and MCP-1 remained elevated. A concave quadratic equation described the associations between plasma venlafaxine concentrations and IL1beta (P=0.03), TNFalpha (P=0.09), and MCP-1 (P=0.02), suggesting that these biomarkers may have become selectively lowered in the serotonergic dose range of venlafaxine. This is the first report of venlafaxine's possible effect on pro-inflammatory biomarkers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Müller, N., Schwarz, M. J., Dehning, S., Douhe, A., Cerovecki, A., Goldstein-Müller, B., Spellmann, I., Hetzel, G., Maino, K., Kleindienst, N., et al. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001805 · Cited by 794
Cytokine Production and Treatment Response in Major Depressive Disorder
Lanquillon, S. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00134-7 · Cited by 735
Pratt, L. A., Ford, D. E., Crum, R. M., Armenian, H. K., Gallo, J. J., & Eaton, W. W. (1996) · Circulation · doi:10.1161/01.cir.94.12.3123 · Cited by 643 · cited 12×
“None of the subjects had symptoms or histories of CAD, nor had they ever been diagnosed as high-risk for CAD.”
BackgroundInfluentialZhu, C.-B., Blakely, R. D., & Hewlett, W. A. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301029 · Cited by 549 · cited 1×
“A final support for the cytokine theory of depression is that pro-inflammatory cytokines alter tryptophan metabolism and serotonin reuptake in ways that favour (e.g., lowering serotonin activity) the development of affective disorders (Palazzolo and Quadri 1992; Zhu et al. 2006).”
BackgroundTuglu, C., Kara, S. H., Caliyurt, O., Vardar, E., & Abay, E. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1566-z · Cited by 391
Th1, Th2, and Th3 cytokine alterations in major depression
MYINT, A., LEONARD, B., STEINBUSCH, H., & KIM, Y. (2005) · Journal of Affective Disorders · doi:10.1016/j.jad.2005.07.008 · Cited by 371
Effects of antidepressants on the production of cytokines
Kenis, G., & Maes, M. (2002) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145702003164 · Cited by 370 · cited 2×
“…of non-SSRI, NRI, or SNRI, antidepressants (of which venlafaxine is an example) to down-regulate cytokines in depression have also been unclear (Kenis and Maes 2002; Tuglu et al. 2003; Kubera et al. 2004; Basterzi et al. 2005; Lee and Kim 2006; Rybakowski et al. 2006; MarquesDeak et al. 2007).”
BackgroundResultKubera, M., Lin, A.-H., Kenis, G., Bosmans, E., van Bockstaele, D., & Maes, M. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200104000-00012 · Cited by 343
Association Between Depression and Elevated C-Reactive Protein
Danner, M., Kasl, S. V., Abramson, J. L., & Vaccarino, V. (2003) · Psychosomatic Medicine · doi:10.1097/01.psy.0000041542.29808.01 · Cited by 341 · cited 3×
“The MCP-1, CD40L, and CRP biomarkers have also been studied, though to a lesser degree (Berk et al. 1997; Danner et al. 2003; Suarez et al. 2003; Leo et al. 2006).”
BackgroundThe psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans
Wichers, M., & Maes, M. (2002) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145702003103 · Cited by 329
Maes, M., Bosmans, E., Suy, E., Vandervorst, C., DeJonckheere, C., & Raus, J. (1991) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1991.tb03163.x · Cited by 268 · cited 1×
“In previous studies, at least two pro-inflammatory cytokines, TNFa and IL1b, have been documented to be elevated in depression (Maes et al. 1991; Tuglu et al. 2003; Thomas et al. 2005; Himmerich et al. 2006).”
BackgroundSuarez, E. C., Krishnan, R. R., & Lewis, J. G. (2003) · Psychosomatic Medicine · doi:10.1097/01.psy.0000035719.79068.2b · Cited by 199 · cited 3×
“The MCP-1, CD40L, and CRP biomarkers have also been studied, though to a lesser degree (Berk et al. 1997; Danner et al. 2003; Suarez et al. 2003; Leo et al. 2006).”
BackgroundThe role of IL-12 and TGF-β1 in the pathophysiology of major depressive disorder
Lee, K.-M., & Kim, Y.-K. (2006) · International Immunopharmacology · doi:10.1016/j.intimp.2006.03.015 · Cited by 150
Treatment of cytokine-induced depression
Capuron, L., Hauser, P., Hinze-Selch, D., Miller, A. H., & Neveu, P. J. (2002) · Brain Behavior and Immunity · doi:10.1016/s0889-1591(02)00007-7 · Cited by 132
Stimulatory effect of antidepressants on the production of IL-6
Kubera, M., Kenis, G., Bosmans, E., Kajta, M., Basta-Kaim, A., Scharpe, S., Budziszewska, B., & Maes, M. (2004) · International Immunopharmacology · doi:10.1016/j.intimp.2003.11.006 · Cited by 126 · cited 4×
“Despite these findings, not all previous studies of antidepressants have been this consistent in regards to the downregulation of pro-inflammatory cytokines (Kenis et al. 2002; Tuglu et al. 2003; Kubera et al. 2004; Basterzi et al. 2005; Lee et al. 2006; Marques-Deak et al. 2007).”
BackgroundResultInfluentialImpairment of Endothelial Function in Unipolar and Bipolar Depression
Rybakowski, J. K., Wykretowicz, A., Heymann-Szlachcinska, A., & Wysocki, H. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.03.025 · Cited by 105 · cited 4×
“…of non-SSRI, NRI, or SNRI, antidepressants (of which venlafaxine is an example) to down-regulate cytokines in depression have also been unclear (Kenis and Maes 2002; Tuglu et al. 2003; Kubera et al. 2004; Basterzi et al. 2005; Lee and Kim 2006; Rybakowski et al. 2006; MarquesDeak et al. 2007).”
BackgroundResultInfluential
Cited by
The Bidirectional Relationship of Depression and Inflammation: Double Trouble
Beurel, E., Toups, M., & Nemeroff, C. B. (2020) · Neuron · doi:10.1016/j.neuron.2020.06.002 · Cited by 2,136
Berk, M., Kapczinski, F., Andreazza, A. C., Dean, O. M., Giorlando, F., Maes, M., Yücel, M., Gama, C. S., Dodd, S., Dean, B., et al. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.10.001 · Cited by 1,178
Haapakoski, R., Mathieu, J., Ebmeier, K. P., Alenius, H., & Kivimäki, M. (2015) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2015.06.001 · Cited by 1,129
Osimo, E. F., Pillinger, T., Rodriguez, I. M., Khandaker, G. M., Pariante, C. M., & Howes, O. D. (2020) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.02.010 · Cited by 937
“…O'brien SM, Scott LV, Dinan TG. , 2006; Nunes et al., 2011; Narita et al., 2006; Munjiza et al., 2018; Motivala et al., 2005; Mota et al., 2013; Piletz et al., 2009; Pike and Irwin, 2006; Pavón et al., 2006; Owen et al., 2001; Ogłodek, 2018; Tuglu et al., 2003; Thomas et al., 2005; Sutcigil…”
Hannestad, J., DellaGioia, N., & Bloch, M. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.132 · Cited by 914
Metadata
- Authors
- Piletz, J. E., Halaris, A., Iqbal, O., Hoppensteadt, D., Fareed, J., Zhu, H., Sinacore, J., & DeVane, C. L.
- Venue
- The World Journal of Biological Psychiatry
- Publisher
- Informa UK Limited
- Published
- 2009-01
- Volume
- 10
- Issue
- 4
- Pages
- 313-323
- ISSN
- 1562-2975 (ISSN-L)
- 1814-1412
- OpenAlex
- W2024969297
- Cited by
- 130
- References
- 16
- FWCI
- 2.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.